Cagrilintide Research Guide: Identity, Literature, Analysis and Documentation
Research use only. StarBio products are supplied strictly for in-vitro laboratory research by qualified professionals. They are not for human or veterinary use, not for diagnostic or therapeutic use, and have not been evaluated by the FDA. This guide covers identity, documentation and handling only. It is not usage guidance.
Cagrilintide is a long-acting analogue of amylin, the 37-residue hormone released with insulin from the pancreas. Three features define it as a material: a fatty diacid attached at the N-terminus, a disulfide bridge near the same end, and an amide at the C-terminus. Each one leaves a signature on a certificate. This page collects the identity data, the research areas the literature covers, the analytical points raised by a lipidated peptide, and the two reports on file for StarBio’s lot.
Identity
| Name | Cagrilintide |
|---|---|
| Type | Synthetic 37-residue amylin analogue, acylated with a C20 fatty diacid |
| CAS number | 1415456-99-3 |
| Molecular weight | 4409.01 g/mol |
| Formula | C194H312N54O59S2 |
| Sequence | 37-residue amylin analog; C20 diacid + gamma-Glu acylation on Lys1; intramolecular disulfide; C-terminal amide |
| Length | 37 amino acids |
Origin and history
Cagrilintide was designed at Novo Nordisk, and its development was described in the Journal of Medicinal Chemistry in 2021. The problem the chemists were solving is old: natural human amylin aggregates into fibrils so readily that it is hard to keep in solution at all. The analogue changes the sequence to resist that and adds a fatty diacid side chain so the molecule binds albumin and persists longer. It was developed as a pharmaceutical and has been studied in large clinical trials, so its literature is clinical. The material StarBio supplies is a synthetic research chemical of the same sequence, sold for laboratory use only. It is not the medicine, and nothing on this page describes a use of it.
What the literature covers
The references on file for this compound span several research areas. They are listed here as areas of study, not as results.
- Design and structure. The 2021 medicinal chemistry paper [6] and a 2025 structural study of binding to the calcitonin and amylin receptors [8].
- Mechanism in animal models. A 2025 study of the brain amylin receptors involved [7].
- Clinical trials. A 2021 trial in The Lancet [4] and two 2025 trials in the New England Journal of Medicine of cagrilintide with semaglutide [2, 3].
- Reviews of the amylin class. Reviews from 2024 and 2025 [1, 5, 10, 11] and a paper on a different amylin agonist, eloralintide [9].
These papers describe a pharmaceutical candidate studied in people and animals. They say nothing about research-grade material.
Analytical notes
At 4409 Da with a fatty side chain, cagrilintide ionises as a series of multiply charged ions, and identity is confirmed by deconvolution to the 4409.0 average mass. The lipid makes it strongly retained on a reverse-phase column and prone to sticking to glass and plastic, so low-binding labware matters for quantitative work. Loss of the fatty chain, an open disulfide (2 Da heavier) and a free acid in place of the C-terminal amide (1 Da heavier) are the changes a careful method looks for.
The two reports on file illustrate why content matters alongside purity. The Janoshik report gives 99.83% purity with 9.48 mg measured against a 10 mg label, and the Medutest report gives 99.48% purity. A high purity figure and a measured mass a little under the label are both true at once, because purity describes what is present and content describes how much. Peptides of the amylin family should also be assumed to aggregate in solution over time, engineered resistance or not.
Storage and stability
- Lyophilized powder
- Store at -20 °C
- Protect from light
- Avoid repeated freeze-thaw cycles
- In solution: 2-8 °C, short term
Documentation for StarBio lots
Every StarBio lot is analysed by an independent laboratory. The table lists the reports on file for this compound.
| Variant | Laboratory / report | HPLC purity | Labelled / measured | Tested | |
|---|---|---|---|---|---|
| Cagrilintide 10 mg | Janoshik Analytical #136380 | 99.83% | 10 mg / 9.48 mg | Apr 22, 2026 | report |
| Cagrilintide 10 mg | Medutest WWB-CGL10-6759 | 99.48% | 10 mg | Feb 11, 2026 | report |
Current certificates are in the COA Library; the verify-lot form connects an order to its batch record.
References
- Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. Cardiology in review, 2024, PMID 36883831.
- Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 2025, PMID 40544433.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. The New England journal of medicine, 2025, PMID 40544432.
- Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet (London, England), 2021, PMID 34798060.
- Amylin analogs for the treatment of obesity without diabetes: present and future. Expert review of clinical pharmacology, 2024, PMID 39317404.
- Development of Cagrilintide, a Long-Acting Amylin Analogue. Journal of medicinal chemistry, 2021, PMID 34288673.
- Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. EBioMedicine, 2025, PMID 40609154.
- Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nature communications, 2025, PMID 40204768.
- Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Molecular metabolism, 2025, PMID 41109426.
- Weight management treatment in obesity. Medicina clinica, 2025, PMID 40865172.
- Amylin, Another Important Neuroendocrine Hormone for the Treatment of Diabesity. International journal of molecular sciences, 2024, PMID 38338796.
Product page: Cagrilintide. Related guides: what 99% purity means, storing lyophilized peptides.
For laboratory research use only. Not for human or veterinary use.
Questions about Cagrilintide
What is Cagrilintide?
Cagrilintide is an acylated amylin analog peptide: 37 residues, molecular weight 4409.01 g/mol, CAS number 1415456-99-3. It is supplied for in vitro laboratory research only. This guide covers identity, documentation and handling, not use.
Is Cagrilintide the same as AM833?
Cagrilintide is also listed as AM833. On a certificate or vial label, the CAS number (1415456-99-3) and the sequence identify the material regardless of which name is used.
What are the CAS number, formula and molecular weight of Cagrilintide?
Cagrilintide has CAS number 1415456-99-3, molecular formula C194H312N54O59S2 and molecular weight 4409.01 g/mol. Sequence: 37-residue amylin analog; C20 diacid + gamma-Glu acylation on Lys1; intramolecular disulfide; C-terminal amide. Identity of each StarBio batch is confirmed by mass spectrometry on the laboratory report.
Is StarBio's Cagrilintide independently tested?
Yes. The current Cagrilintide batch was tested by Janoshik Analytical (Janoshik Analytical report #136380): 99.83% purity by HPLC, measured content 9.48 mg against 10 mg labelled, tested Apr 22, 2026. The report is on file in the COA library (report page). Janoshik Analytical reports can be checked on janoshik.com with the report number.
How should Cagrilintide be stored?
Lyophilized powder; Store at -20 °C; Protect from light; Avoid repeated freeze-thaw cycles; In solution: 2-8 °C, short term. StarBio ships it as sealed lyophilized powder.
Where can I buy Cagrilintide for laboratory research?
StarBio sells Cagrilintide as 10 mg at $69.99, shipped tracked from Florida to all 50 US states. StarBio does not ship internationally. Buyers must be qualified researchers or institutions aged 21 or older, buying for in vitro laboratory work.
New reports and guides, by email
A short note when a new laboratory report is published, when a compound returns to stock, and when a new guide goes up. Nothing else. Leave whenever you like.
For laboratory research use only. No dosing or protocol content is ever sent.

